Iovance Biotherapeutics (IOVA) Change in Accured Expenses (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Change in Accured Expenses for 15 consecutive years, with -$21.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1035.02% year-over-year to -$21.0 million; the TTM figure through Mar 2026 stood at $5.3 million (down 84.19% YoY), while the FY2025 annual figure was $28.6 million, up 233.84% from the prior year.
• Change in Accured Expenses fell to -$21.0 million in Q1 2026 per IOVA's latest filing, from $21.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $21.2 million in Q4 2025 and bottomed at -$23.0 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $1.8 million across 5 years, with a median of $3.5 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 934.65% — and 2026, when it sank 1035.02%.
• Iovance Biotherapeutics' Change in Accured Expenses stood at $909000.0 in 2022, then surged by 934.65% to $9.4 million in 2023, then tumbled by 56.58% to $4.1 million in 2024, then soared by 418.34% to $21.2 million in 2025, then plunged by 199.38% to -$21.0 million in 2026.
• Business Quant data shows IOVA's Change in Accured Expenses at -$21.0 million in Q1 2026, $21.2 million in Q4 2025, and $5.5 million in Q3 2025.